Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Research & Development (2016 - 2025)

KalVista Pharmaceuticals' Research & Development history spans 11 years, with the latest figure at $15.9 million for Q2 2025.

  • For Q2 2025, Research & Development fell 37.06% year-over-year to $15.9 million; the TTM value through Apr 2025 reached $84.4 million, down 2.09%, while the annual FY2025 figure was $71.7 million, 16.78% down from the prior year.
  • Research & Development for Q2 2025 was $15.9 million at KalVista Pharmaceuticals, down from $16.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $26.6 million in Q3 2024 and bottomed at $9.1 million in Q1 2021.
  • The 4-year median for Research & Development is $19.2 million (2023), against an average of $19.3 million.
  • The largest annual shift saw Research & Development skyrocketed 37.85% in 2024 before it plummeted 37.06% in 2025.
  • A 4-year view of Research & Development shows it stood at $9.1 million in 2021, then skyrocketed by 109.84% to $19.1 million in 2023, then fell by 12.98% to $16.6 million in 2024, then decreased by 4.34% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Research & Development are $15.9 million (Q2 2025), $16.6 million (Q4 2024), and $26.6 million (Q3 2024).